August 24, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Company
News Sectors
Automotive
Communications
Consumers
CSR
Electronics
Energy
Environment
Financial
Health & Med
Industrial
IT & Internet
Materials
Real Estate
Science & Research
Telecoms
Trade
Transportation
Departments
Annual Reports
Companies
News Alerts
News Search
Photo Gallery
Company Login
Japan Corporate News Network
About JCN
Privacy Policy
RSS  
Terms of Use
 
 
 

 Headline News

Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Mitsui & Co. has invested in "KIFMEC specific purpose company" which has been established in order to lease a hospital building to Kobe International Frontier Medical Center ("KIFMEC"). more info >>
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Nitto Denko Corporation has been developing a new RNAi based drug for treating fibrosis in liver and other organs since 2008 in collaboration with Prof. Yoshiro Niitsu of Sapporo Medical University. more info >>
ACN Newswire
 Press Release News

Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S. (Aug 20, 2014)
Eisai Co., Ltd. announced today that it has submitted applications to regulatory authorities in the U.S. and Europe (the FDA and EMA respectively) for the indication expansion of its in-house developed antiepileptic drug Fycompa as an adjunctive treatment of primary generalized tonic-clonic seizures (PGTC). more info >>
Eisai and Zeria Conclude License Agreement Concerning a New Portion Pump Inhibitor in Japan (Aug 18, 2014)
Eisai Co., Ltd. and Zeria Pharmaceutical Co., Ltd. announced today that they have concluded a license agreement concerning E3710, a novel proton pump inhibitor (PPI) discovered and developed in-house by Eisai. more info >>
Eisai Supports Earthquake Relief Efforts in Yunnan, China (Aug 7, 2014)
Eisai expresses its heartfelt sympathies to all those affected by the recent earthquake which occurred in Ludian county of Zhaotong city, Yunnan province, China. more info >>
EMA Grants Eisai's Anticancer Agent Lenvatinib Request for Accelerated Assessment (July 31, 2014)
Eisai Co., Ltd. announced today that its U.K. subsidiary Eisai Europe Ltd. has been granted an accelerated review by the European Medicines Agency (EMA) for its in-house developed anticancer agent lenvatinib mesylate in the treatment of radioiodine-refractory differentiated thyroid cancer. more info >>
Eisai Receives European Commission Approval of Indication Expansion for Anticancer Agent Halaven for Advanced Breast Cancer After Only One Prior Chemotherapy (July 3, 2014)
Eisai Co., Ltd. announced today that it has received approval from the European Commission of the indication expansion of Halaven to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. more info >>
 Global Press Release

Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S. (Aug 20, 2014)

Eisai and Zeria Conclude License Agreement Concerning a New Portion Pump Inhibitor in Japan (Aug 18, 2014)

Eisai Supports Earthquake Relief Efforts in Yunnan, China (Aug 7, 2014)

EMA Grants Eisai's Anticancer Agent Lenvatinib Request for Accelerated Assessment (July 31, 2014)

A*STAR Partners Roche to Develop New Cancer Therapeutics (July 14, 2014)

JCN Network - Company Profiles - Company Listing
 
CSR Report Download
Most Popular
About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)